# Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

> **NCT00873041** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 166 (actual)

## Conditions studied

- Non-transfusion Dependent Thalassemia

## Interventions

- **DRUG:** deferasirox
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00873041
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2011-06
- **Final completion:** 2012-06
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2013-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00873041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00873041, "Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00873041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*